KRAS and cancer: It could be postulated that the superior outcomes of the patients in the present study were partly due to the selection of patients with Kras wild-type tumor; patients were treated with bevacizumab at a time when the cancer cells had become more dependent on the VEGF pathway upon acquiring resistance to the EGFR inhibitor.